Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...

Researchers have developed a non-addictive painkiller that remains inactive until it reaches sites of chronic pain. Instead of dulling the nerves that send the pain signals like other analgesics, this ...

Rather than merely masking pain signals like conventional analgesics, this new medication directly tackles the root cause of ...

Pharmacological treatment is usual in this case, but other therapeutic possibilities can help relieve the discomfort without the side effects caused by drugs ... pain caused by diabetic neuropathy ...

Scientists have designed a groundbreaking painkiller that activates solely at chronic pain sites, offering targeted, ...

“We are working with urgency to file the new drug application for ... also be effective in neuropathic pain experienced by patients with diabetic peripheral neuropathy, which doesn’t tend ...

Oct. 16, 2024 — According to new research, men and women rely on different biological systems for pain relief, which could help explain why our most powerful pain medications are often less ...

Often seen as a safer alternative to opioids for the treatment of neuropathic pain, gabapentinoid use increased eightfold between 2012 and 2018, with one in seven Australians aged 80 and older ...

Pain. 2014;155(12):2461-70.. Although pathogenesis and toxicity profiles differ among potentially neurotoxic agents, there are some features which allow the differentiation of chemotherapy-induced NP ...